Navigation Links
Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
Date:5/20/2009

WILMINGTON, Del., May 20 /PRNewswire-FirstCall/ -- On May 20, 2009, the US District Court for the District of New Jersey granted the request of AstraZeneca (NYSE: AZN) for an injunction barring Apotex (Apotex, Inc. and Apotex Corp.) from launching a generic version of AstraZeneca's PULMICORT RESPULES (budesonide inhalation suspension) in the US. No trial date for the patent litigation has been set.

On March 30, 2009, the US Food and Drug Administration granted approval for a generic version of AstraZeneca's PULMICORT RESPULES to Apotex. AstraZeneca then filed suit following Apotex's indication of intent to market a generic version of AstraZeneca's PULMICORT RESPULES in the US prior to the expiration of AstraZeneca's patents.

AstraZeneca has full confidence in the strength of its intellectual property rights protecting PULMICORT RESPULES and will continue to vigorously defend and enforce its intellectual property.

Patents covering PULMICORT RESPULES expire in 2018 with pediatric exclusivity extending to 2019.

About PULMICORT RESPULES

PULMICORT RESPULES is a preventive, maintenance asthma medicine indicated for use in children 12 months to 8 years of age in the United States. Full-year US sales for PULMICORT in 2008 totalled $982 million, about 90 percent of which is accounted for by PULMICORT RESPULES.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. A
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Texas Supreme Court Rules Against Medicare HMOs in Hospital Reimbursement Fight
2. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
3. First Circuit Court of Appeals Rules Against Philip Morris in Lights Class Action
4. Wyeth and Nycomed Announce Court Denial of Preliminary Injunction
5. Massachusetts State Court Hears Suit by Breastfeeding Mother on Medical Licensing Exam
6. Cristina Saralegui Joins Celebrities Including Matthew McConaughey, Courteney Cox and Mariska Hargitay to Raise Money for Breast Cancer Research
7. Filing for Reconsideration/Press Conference ACUNA v. TURKISH, Historic Informed Consent Abortion Case to the New Jersey Supreme Court
8. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
9. NBME Appeals Massachusetts Judges Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam
10. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
11. ALLs Judie Brown: Supreme Court is Wrong on Contraception Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 SB 277 (CA ... for children to attend public or private school. SB277 ... but bypassed the Appropriations Committee (Sacramento Bee, May 11, ... contentious hearings. , “We believe that this bill ... (PBEs) more than it will (the) affect public health ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Specialty ... audit, compliance and risk solutions , and Radar ... risk management effectiveness gap-improvement program. , All organizations ... uncertainty on objectives. Organizations not only assess and ... capabilities to do this (risk managing) thereby embedding ...
(Date:6/1/2015)... The National Association of Professional ... a 2015-2016 inductee into its VIP Woman of the ... for leadership in business. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Job satisfaction is essential ...
(Date:6/1/2015)... The National Association of Professional Women ... 2015-2016 inductee into its VIP Woman of the Year ... leadership in life coaching. NAPW is the nation’s leading ... 700,000 members and over 200 operating Local Chapters. , ... said NAPW President Star Jones. “Her work as a ...
Breaking Medicine News(10 mins):Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcy Herrmann, Therapist, Life Coach, Advanced Handwriting Analyst, Into its VIP Professional Woman of the Year Circle 2
... Pharmacologic Data Presented at American Association for Cancer Research,s ... DENVER, April 21 Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced the presentation of final data from a ... picoplatin in patients with solid tumors. Results showed that ...
... April 21 Bio-Optronics, Inc. will enhance ... with click-through integration to Interspond,s RxPaying(TM) debit ... payment alternative which improves efficiency and increases ... points in clinical trial workflow into which ...
... Scenic ride and summer weekend fun ahead in Gladstone GLADSTONE, ... Cross is teaming up with several area groups and businesses to ... with the first annual "Da, U.P. Ride for the Red" on ... Friday, July 17, local food vendors will offer their fares. Beer ...
... clopidogrel can be prescribed to patients with acute ischaemia ... (ASA). The Institute for Quality and Efficiency in Health ... clopidogrel and ASA actually has a higher benefit for ... published on 31 March 2009, concludes that combination therapy ...
... April 21 More people are turning to ... their medical condition - tattooing. A case ... the American Association of Clinical Endocrinologists (AACE) 18th ... this new phenomenon, while urging discussion from the ...
... 21 Hill-Rom Holdings, Inc.,s, (NYSE: HRC ) fiscal ... 2009. You are invited to participate in a webcast the ... Earnings Release: Hill-Rom Holdings, Inc.,s Fiscal 2009 Second ... released to the public after the NYSE close on Monday, May ...
Cached Medicine News:Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 2Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 3Health News:Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability 4Health News:Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS) 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 2Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 3Health News:ASA plus clopidogrel reduces heart attack risk in patients with acute coronary syndrome 4Health News:New Research Reveals Need for Doctors to Know About Medical Tattoos 2Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Second Quarter Earnings Webcast 2
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MECHANICSBURG, Pa. , June 1, 2015 ... announced that MJ Acquisition Corporation, a joint venture that ... Stowe XII, L.P., has completed its previously announced acquisition ... in the new joint venture. About ... leading operator of specialty hospitals and outpatient rehabilitation clinics ...
(Date:6/1/2015)... 1, 2015 NEOVIA ONCOLOGY Ltd. ... the development and commercialization of novel, multi-function drugs ... met with the U.S. Food and Drug Administration ... an Investigational New Drug (IND) application for its ... of the meeting, Neovia has clarified details of ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 2Select Medical Holdings Corporation Announces Completion of Acquisition of Concentra Inc. through Joint Venture with Welsh Carson 3Neovia Oncology Announces First IND Meeting 2
... Feb.5 Cytopia Limited (ASX: CYT) has successfully ... for CYT997, the company,s anticancer vascular-disrupting agent (VDA). ... study have been achieved. These were to determine ... toxicities (DLTs) for the agent when administered orally ...
... (OTCBB: ORMP.OB), a developer of alternative drug,delivery systems, ... of concept,study in South Africa of insulin suppositories, ... for two visits, with,two different formulations. , ... insulin absorption and reactive,glucose lowering effect. The suppositories ...
Cached Medicine Technology:Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 2Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 3Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997 4Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository 2
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
... family of 100% latex-free ... variety of options for ... catheter is made of ... and has smooth fire ...
Used for intermittent catheterization of a male or female patient to provide drainage of urine from the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... An indirect immunofluorescence antibody test ... anti-neutrophil cytoplasmic antibodies (ANCA) in human ... sera of patients with necrotizing vasculitides ... to the clinical and other laboratory ...
Medicine Products: